Disease profile of Guillain-Barré syndrome among Indian patients receiving intravenous immunoglobulin: a real-world observational study

Abstract

<p class="abstract"><strong>Background:</strong> Objectives of the study were to evaluate the real-world usage pattern of intravenous immunoglobulin (IVIg) for the treatment of patients with Guillain‐Barré syndrome (GBS), and to understand the disease characteristics and demographic patterns of these patients.</p><p class="abstract"><strong>Methods:</strong> This real-world, retrospective, analysis included data of patients with GBS who received IVIg treatment at various centers across India. The study data was collected between April 2021 and March 2022. </p><p class="abstract"><strong>Results:</strong> A total of 3064 patients with GBS who received IVIg treatment were included. The mean (SD) age of the patients was 48.97 (14.97) years, and majority of the patients were men (68.8%). Acute inflammatory demyelinating polyneuropathy (AIDP) was the most common subtype of GBS (60.5%), followed by acute motor axonal neuropathy (AMAN; 11.6%), and acute motor sensory axonal neuropathy (AMSAN; 3%). The majority (>94%) of patients received IVIg therapy as first-line treatment. A large proportion of the patients (n=2402, 78.4%) were given the standard dose of 2 g/kg bodyweight (given over 5 days) and 97.1% (n=2974) of the total study population received IVIg regimen over the standard protocol of 5 days.</p><p class="abstract"><strong>Conclusions:</strong> In the clinical spectrum of GBS, AIDP was the most common subtype. IVIg was used at generally recommended dose and duration in patients with GBS.</p>